Clinical Trials Directory

A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma

This phase II trial is studying how well sorafenib works in treating patients with recurrent diffuse large B-cell non-Hodgkin's lymphoma. Sorafenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.

Stanford is not currently accepting new patients for this trial. You may want to check clinicaltrials.gov to see if other locations are recruiting.

Investigator(s):

Intervention(s):

  • drug : sorafenib tosylate

Phase: Phase 2

Eligibility

Ages Eligible For Study:

18 Years - N/A

Inclusion Criteria

- Patients must have histologically confirmed recurrent de novo or transformed diffuse large B cell lymphoma (DLBCL) or one of its variants according to WHO classification (centroblastic, immunoblastic, T-cell/histiocyte rich and anaplastic variants) - Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1 - Patients must have measurable disease as defined in section 6 assessed within 4 weeks of registration - Patients must have failed one or more prior Non-Hodgkin lymphoma (NHL) chemotherapy or antibody therapy with curative intent; autologous stem cell transplant is permitted - Leukocytes >= 2,000/mm^3 - Absolute neutrophil count >= 1,000/mm^3 - Platelets >= 75,000/ mm^3 - Total bilirubin =< 2.0 X normal institutional limits - Aspartate Aminotransferase (AST) =< 2.5 X institutional upper limit of normal - Alanine Aminotransferase (ALT) =< 2.5 X institutional upper limit of normal - Creatinine within normal institutional limits; creatinine clearance calculated or measured at >= 60 ml/min/1.73m^2 if creatinine level is above institutional limits - The prothrombin time (PT)/international normalized ratio (INR) within Institutional limits of normal - Patients with underlying hypertension as defined by blood pressures averaging greater than 140/90 on two separate clinic visits are eligible if hypertension has been controlled by standard nonpharmacologic and pharmacologic therapy - Patients must be physically able to orally ingest tablets

External Links

Explore related trials

Contact information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Sarah Daadi
6507256456
Not Recruiting

Footer Links: